1. Introduction {#sec1}
===============

Remodelling of the extracellular matrix (ECM) is crucial for adipogenesis [@bib1], [@bib2]. Mounting data indicate that altered expression of ECM components such as collagen [@bib3] and hyaluranon [@bib4] can modify adipose tissue (AT) function and thereby influence overall metabolic health. Adipocytes within AT are embedded in a three-dimensional ECM scaffold whose spatial arrangement is co-ordinated by matricellular proteins; these proteins physically interact with ECM components but do not directly contribute to the ECM\'s structural integrity [@bib5]. Matricellular proteins are secreted modular molecules implicated in numerous processes ranging from proliferation, migration, and differentiation to angiogenesis and wound healing [@bib6]. The thrombospondins comprise five calcium-binding matricellular proteins that regulate AT biology.

Thrombospondin-1 (THBS1) is an adipokine implicated in the development of obesity and metabolic disease [@bib7]. The *THBS1* gene is more highly expressed in visceral compared to subcutaneous abdominal AT [@bib8] with mRNA levels in the latter reportedly correlating positively with BMI but correlating negatively with insulin sensitivity [@bib9]. Further, circulating THBS1 protein levels were found to positively correlate with hypertension, hyperglycaemia, and central obesity in a Japanese cohort [@bib10]. *Thbs1* knock-out mice are protected from the deleterious effects of high-fat diet feeding [@bib11], [@bib12], [@bib13]. Thbs2 has also been reported to exert anti-adipogenic effects in mice [@bib14] although this finding has not been replicated [@bib15].

*THBS5* (also called cartilage oligomeric matrix protein; COMP) exhibits a striking depot-specific expression pattern between subcutaneous abdominal and gluteal AT [@bib16]. Given that most differentially-expressed genes between white AT depots tend to be development-related transcriptional regulators such as *HOX* genes [@bib16], [@bib17], [@bib18], regional variation in the expression of ECM components may be important in the context of depot-specific AT biology.

COMP has primarily been studied in the context of bone as mutations in *THBS5* cause severe skeletal malformations, principally pseudoachondroplasia (PSACH) [@bib19]. COMP coordinates collagen fibrillogenesis [@bib20], but PSACH-causing mutations disrupt this process [@bib21], typically by causing intracellular retention of mutant COMP protein which results in chondrocyte death [@bib22]. It has been proposed that plasma COMP protein levels represent a biomarker of osteoarthritis progression [@bib23]. With central obesity being associated with an increased risk of developing metabolic and cardiovascular disease as well as osteoarthritis [@bib24], there is a growing appreciation of cross-talk between bone and AT via circulating factors in health and disease [@bib25]. Based on its multi-functional properties and well-established role in cartilage/bone biology, COMP is an attractive candidate molecule to study in the context of AT. The aim of this study was to investigate *COMP* expression in human subcutaneous abdominal and gluteal AT and preadipocytes and relate this to AT distribution and function.

2. Methods {#sec2}
==========

2.1. Immunohistochemistry {#sec2.1}
-------------------------

AT biopsies collected via gun biopsy under local anaesthetic (1% lignocaine) were fixed in 10% formaldehyde, embedded in paraffin wax, and cut into 5 μm sections. Sections were dewaxed, rehydrated (ethanol), and antigen retrieval was performed (heating in 1 mM sodium citrate). Endogenous peroxidase activity was blocked (0.3% H~2~O~2~ in methanol), and auto-fluorescence was quenched (1.5% glycine). Sections were blocked in 1/20 swine serum (Dako) and incubated with goat anti-COMP (1/100; AF3134; R&D Systems) and rabbit anti-collagen 1 (1/300; ab34710; Abcam) overnight at 4 °C. Sections were washed and incubated with horseradish peroxidase (HRP)-conjugated donkey anti-goat antibody (1/50; sc2020; Santa Cruz Biotechnology) to label COMP staining; the signal was amplified via tyramide amplification (0.3% H~2~O~2~ with 5% tyramide 488). Sections were then blocked in 1/20 goat serum (Dako) and incubated in goat anti-rabbit 568 (1/250; A11036; Life Technologies) to co-label collagen 1 staining. Sections were mounted and visualised using a Radiance 2100 laser scanning system confocal microscope (Bio-Rad); images were captured using Laser sharp software (Bio-Rad).

2.2. AT sample collection {#sec2.2}
-------------------------

Paired AT samples were taken from 97 females and 93 men in the Oxford Biobank (OBB) [@bib26] by needle biopsy from the periumbilical (subcutaneous abdominal AT) and upper buttock (gluteo-femoral AT) areas under local anaesthetic (1% lignocaine) and immediately stored in RNAlater (ThermoFisher Scientific). Donors had a median age of 45 years (range 33--53 years) and median body mass index (BMI) of 25.6 kg/m^2^ (range 18.8--46.2 kg/m^2^). The taking of human AT samples was approved by the Oxfordshire Clinical Research Ethics Committee; all participants gave written informed consent.

2.3. Preadipocyte culture and differentiation {#sec2.3}
---------------------------------------------

Immortalised subcutaneous abdominal and gluteal preadipocyte cell lines were generated, maintained and differentiated as recently described [@bib27]. COMP (ACRO Biosystems) reconstituted as previously described [@bib28] was added to the growth medium or adipogenic cocktail where indicated.

2.4. Gene expression analysis {#sec2.4}
-----------------------------

Total RNA was extracted from AT biopsies [@bib29] and preadipocytes [@bib30]. cDNA was synthesised from total RNA using the High Capacity cDNA Reverse Transcription Kit (Life Technologies). Quantitative (q)-PCR was performed on cDNA diluted 1/20 in triplicate with Kapa Probe Fast Mastermix (Kapa Biosystems) in an 8 μl reaction. The following TaqMan Assays-on-Demand (Applied Biosystems) were used: *COMP* (Hs00164359_m1); *PPARG2* (Hs01115510_m1); *FASN* (Hs00188012_m1); and *PPIA* (Hs99999904_m1). Data were captured on an ABI Prism 7900 HT. Relative transcript expression was calculated using the ΔΔCt relative quantification methods [@bib31] where:

The ΔCt values of target genes were normalised to ΔCt of the reference transcript *peptidylprolyl isomerase A* (*PPIA*).

2.5. Western blotting {#sec2.5}
---------------------

Whole AT biopsies lysates were prepared using an IKA homogeniser in ice-cold lysis buffer (8 M Urea; 1% SDS; 5% glycerol; 10 mM Tris--HCl; pH 6.8) and protease inhibitor cocktail (Complete EDTA-free; Roche). Whole cell lysates were processed as previously described [@bib27]. Equal amounts of protein were loaded (50 μg/biopsy; 100 μg/cell lysate) and resolved by SDS-PAGE, transferred onto polyvinylidene (PVDF) membranes (Bio-Rad) and immunoblotted with: COMP (0.1 μg/ml; AF3134; R&D Systems); β-actin (1:2000; sc1616; Santa Cruz); and α-tubulin (1:2000; ab15246; Abcam) antibodies followed by an HRP-conjugated secondary antibody; goat anti-rabbit IgG (1:5000; 31460; ThermoFisher Scientific). Clarity enhanced chemiluminescence detection kit (Bio-Rad) was used for detection. Immunoblot images were captured on a Chemi-Doc XRS+ (Bio-Rad) and analysed using ImageJ (National Institute of Health, USA) software.

2.6. Measurement of cellular triacylglycerol content {#sec2.6}
----------------------------------------------------

Adipocyte triacylglycerol (TAG) content was measured in differentiated immortalised subcutaneous abdominal and gluteal preadipocytes on day 14 of adipogenesis using an ILAB 650 clinical analyser (Instrumentation Laboratory UK) according to the previously described method [@bib27].

2.7. Quantification of plasma and cell media COMP concentrations {#sec2.7}
----------------------------------------------------------------

COMP concentration in preadipocyte-conditioned media and plasma was determined using ELISA (R&D Systems) in duplicate. Plasma samples were selected from participants in the OBB with distinctly different AT distribution phenotypes. Using dual X-ray absorptiometry-derived body composition data on 4900 participants, individuals from the top vs. lowest tertile of Android/Gynoid fat mass ratio were pair matched for total fat mass percentage, age, and sex (80 men; 72 women). Anthropometric characteristics for the study cohorts are presented in [Supplementary Information Table 1](#appsec1){ref-type="sec"}. Depot-specific COMP release by AT into the bloodstream was measured using arterio-venous plasma samples (9 healthy lean women in the fasted state) obtained as previously described [@bib32].

2.8. Data analysis and statistics {#sec2.8}
---------------------------------

Data are presented as means ± SEM. Statistical analyses were performed in SPSS Statistics version 22 (IBM). Statistical tests used were as described in the results section. Differences were considered statistically significant at P \< 0.05.

3. Results {#sec3}
==========

3.1. COMP is highly differentially expressed between subcutaneous abdominal and gluteal AT {#sec3.1}
------------------------------------------------------------------------------------------

Our previous transcriptomic array data indicated that *COMP* was significantly more highly expressed in subcutaneous gluteal AT compared to abdominal AT [@bib16]. qPCR analysis of unselected paired subcutaneous abdominal and gluteal AT biopsies (n = 190) across a range of BMI (20.7--45.5 kg/m^2^) validated the previous microarray data and showed that *COMP* expression was ∼3-fold higher in gluteal AT (P = 1.7 × 10^−31^) ([Figure 1](#fig1){ref-type="fig"}A). Consistent with the qPCR data, Western blot analysis of paired AT biopsies showed that COMP protein levels exhibited the same depot-specific expression pattern ([Figure 1](#fig1){ref-type="fig"}A). Immunohistochemistry analysis of (obese gluteal) AT highlighted that COMP protein was present throughout the ECM, including within the perivascular space, and co-localised with collagen-1 ([Figure 1](#fig1){ref-type="fig"}A).Figure 1***COMP* is differentially expressed between abdominal and gluteal AT**. (A) Left graph, *COMP* expression in abdominal and gluteal AT (corrected for age, sex and BMI). Right graph, COMP protein levels (normalised to α-tubulin) in paired AT biopsies (n = 6 healthy females) including representative blot. Data provided as mean ± SEM. Representative immunohistochemistry image of (obese gluteal) AT for COMP (green) and collagen 1 (red) staining; white arrows highlight co-localisation (yellow). (B) Left graph, *COMP* mRNA levels (n = 6) and right graph, COMP protein levels (n = 3) in proliferating immortalised subcutaneous abdominal and gluteal preadipocytes. (C) Left graph, *COMP* mRNA levels (n = 3) and right graph, COMP protein levels (n = 3) in differentiated immortalised subcutaneous abdominal and gluteal preadipocytes. *COMP* mRNA levels normalised to *PPIA* and protein levels normalised to β-actin. Data presented as mean ± SEM; analysed via paired T-test; \*P \< 0.05.Figure 1

Analysis of *COMP* expression in immortalised preadipocytes showed that its depot-specific expression pattern was retained *ex vivo* at the level of transcription and translation. *COMP* mRNA and protein levels were significantly higher in proliferating gluteal preadipocytes compared to abdominal cells ([Figure 1](#fig1){ref-type="fig"}B); this depot-specific expression pattern was recapitulated in differentiated preadipocytes ([Figure 1](#fig1){ref-type="fig"}C). Collectively, these data confirm that *COMP* is highly differentially expressed between abdominal and gluteal AT and that this expression pattern was retained *ex vivo*.

3.2. COMP expression in subcutaneous AT is enhanced in obesity {#sec3.2}
--------------------------------------------------------------

It has been proposed that other members of the thrombospondin family, particularly THBS1, represent adipokines [@bib9], [@bib10]. Previous literature indicate that COMP is readily detectable in plasma [@bib33] so we investigated whether COMP represents a novel adipokine by measuring the arterio-venous concentration difference across human subcutaneous AT using a previously described method [@bib32]. To investigate this whilst accounting for the differential expression pattern of *COMP*, plasma samples taken across subcutaneous abdominal and gluteal AT (from 9 healthy, lean women in the fasted state) were analysed via ELISA to determine whether COMP protein was released by AT in a depot-specific manner. Although COMP was detectable in plasma, the arterio-venous difference in COMP protein concentration was not different from zero, thus indicating there was no measurable release of COMP from either abdominal or gluteal subcutaneous AT in these individuals (data not shown).

As the rate of COMP production and release by AT may be too slow to allow for detection using the arterio-venous difference technique (as for adiponectin [@bib34]), we set out to determine whether circulating COMP levels could be used as an index of long-term COMP turnover in AT. We therefore hypothesised that plasma COMP levels would be higher in individuals with preferential lower body fat accumulation given the higher expression of *COMP* in gluteal AT. To test this, plasma COMP protein levels were measured in individuals exhibiting either predominantly abdominal or gluteo-femoral AT accumulation but matched for overall AT mass across a range of BMI. OBB data were sorted according to Android/Gynoid fat mass ratio (quantified via dual X-ray absorptiometry); individuals were selected from the top tertile (i.e. centrally-distributed AT) and matched to a corresponding individual from the lowest tertile (i.e. peripherally-distributed AT) with the same total fat mass percentage (+/−1%); individuals were also matched for age (+/−1 year) and sex. The anthropometric characteristics of the study participants are detailed in [Supplementary Table 1](#appsec1){ref-type="sec"}.

Plasma COMP protein levels were significantly higher in men than women (Mann--Whitney U-test, P = 0.0002), so the data were separated by sex for further analyses. Pairwise analysis of the 40 men ([Figure 2](#fig2){ref-type="fig"}A) and 36 women ([Figure 2](#fig2){ref-type="fig"}B) pairs highlighted there was no significant difference in circulating COMP protein levels between individuals with opposite body fat distribution phenotypes. However, when the data were sorted according to BMI, it was found that circulating COMP protein levels were significantly higher (Mann--Whitney U-test) in overweight/obese (BMI \>25 kg/m^2^) men (P = 0.007) and women (P = 0.019) compared to their lean (BMI \<25 kg/m^2^) counterparts ([Figure 2](#fig2){ref-type="fig"}C). Consistent with this, plasma COMP protein levels were positively correlated with total fat mass percentage in men (Spearman\'s rho = 0.352, P = 0.001) and women (Spearman\'s rho = 0.315, P = 0.007). Collectively, these data support the notion that *COMP* expression reflects overall adiposity. However, it was not possible to confirm whether COMP behaved as an adipokine in the sense that it is released from AT to act on a distant target tissue.Figure 2***COMP* expression in AT is enhanced in obesity.** Plasma COMP protein concentration in men (A) (n = 80) and women (B) (n = 72) matched to individual with same total fat mass % but opposite Android/Gynoid fat mass ratio (And/Gyn); each line connects a matched pair. (C) Plasma COMP protein concentration stratified by BMI (kg/m^2^). Data presented as mean ± SEM; data in A, B and C analysed via Mann--Whitney U-test; \*P \< 0.05. *COMP* mRNA levels (normalised to *PPIA*) in subcutaneous abdominal (Abd) and gluteal (Glut) AT in men (D) (n = 93) and women (E) (n = 97) stratified by BMI (kg/m^2^). Data presented as age-adjusted means ± SEM; data analysed via ANOVA (with post-hoc T-tests); \*P \< 0.05 compared to lean expression in same depot; ^\#^P \< 0.05 compared to overweight expression in same depot.Figure 2

Building on these data, we investigated whether *COMP* expression in AT was related to the degree of adiposity and/or regional AT distribution. This involved measuring *COMP* mRNA levels in paired AT biopsies obtained from 190 OBB participants and relating expression to various anthropometric parameters (DXA data were not available for these individuals). According to conventional BMI cut-offs, *COMP* mRNA levels were significantly higher in obese men ([Figure 2](#fig2){ref-type="fig"}D) and women ([Figure 2](#fig2){ref-type="fig"}E) compared to their overweight and lean counterparts in both abdominal and gluteal AT (analysis of variance - ANOVA - with post-hoc T-tests). The ratio of abdominal/gluteal AT *COMP* mRNA levels was not significantly different between BMI groups, thus indicating that *COMP*\'s depot-specific expression pattern was maintained across the range of adiposity (data not shown).

More detailed analyses (Partial Pearson\'s correlation with correction for age) showed a strong positive correlation between abdominal and gluteal AT *COMP* mRNA levels and BMI in both men and women ([Table 1](#tbl1){ref-type="table"}A). Similar positive correlations were detected between abdominal and gluteal AT *COMP* mRNA levels and waist and hip circumference as well as fasting plasma insulin (a reverse index of whole body insulin sensitivity) in men and women ([Table 1](#tbl1){ref-type="table"}A). However, these relationships were principally driven by BMI as most became non-significant after correcting for BMI barring female hip circumference and male fasting insulin which remained nominally significant ([Table 1](#tbl1){ref-type="table"}B).Table 1A. Partial Pearson\'s correlation analysis (corrected for age) for (log-transformed) AT *COMP* mRNA levels (normalised to *PPIA*) with anthropometric and biochemical parameters in abdominal (Abd) and gluteal (Glut) AT. B. Partial Pearson\'s correlation analysis (corrected for age and BMI) for (log-transformed) AT *COMP* mRNA levels (normalised to *PPIA*) with anthropometric and biochemical parameters. Right-hand column - correlation analysis between (log-transformed) *COMP* mRNA levels (normalised to *PPIA*) and BMI (corrected for age and fasting plasma insulin).Table 1A -- Age-corrected correlationsBMIWaist circumferenceHip circumferenceFasting InsulinPearsonPPearsonPPearsonPPearsonPMenLog Abd COMP0.4007.0 × 10^−5^\*0.3500.001\*0.3380.001\*0.4842.0 × 10^−6^\*Log Glut COMP0.3290.001\*0.2910.006\*0.2940.005\*0.1940.070WomenLog Abd COMP0.5293.0 × 10^−8^\*0.4632.0 × 10^−6^\*0.3702.1 × 10^−4^\*0.3986.0 × 10^−5^\*Log Glut COMP0.4241.6 × 10^−5^\*0.3908.6 × 10^−5^\*0.3610.003\*0.3584.0 × 10^−4^\*B -- Age and BMI-corrected correlationsWaist circumferenceHip circumferenceFasting InsulinBMIPearsonPPearsonPPearsonPPearsonPMenLog Abd COMP−0.0680.530−0.0450.6700.3200.002\*0.2470.02\*Log Glut COMP−0.0520.630−0.0080.9400.0020.9900.2990.005\*WomenLog Abd COMP−0.0220.840−0.2140.037\*0.1170.2600.4456.0 × 10^−6^\*Log Glut COMP−0.0290.780−0.0170.8700.1460.1600.3100.02\*[^1]

As these data suggested that insulin might exert an independent effect on *COMP* expression, we corrected the correlation between *COMP* mRNA levels and BMI for fasting plasma insulin but it remained statistically significant ([Table 1](#tbl1){ref-type="table"}B). Consistent with this, administration of insulin (100 nM) to proliferating immortalised subcutaneous abdominal or gluteal preadipocytes for 24 h did not increase *COMP* expression (data not shown). Overall, abdominal and gluteal AT *COMP* mRNA levels were strongly positively correlated with BMI in men and women, thus suggesting that AT *COMP* expression reflects overall adiposity.

3.3. COMP is a positive adipogenic regulator {#sec3.3}
--------------------------------------------

During a standard 14 day differentiation protocol, *COMP* mRNA levels were found to change dynamically in immortalised human subcutaneous abdominal and gluteal preadipocytes ([Figure 3](#fig3){ref-type="fig"}A). More specifically, *COMP* mRNA levels declined between days 2--10 before returning to the higher baseline levels toward the end of the differentiation protocol. While *COMP* mRNA levels fluctuated, its depot-specific expression pattern was always maintained.Figure 3**COMP is a positive adipogenic regulator**. (A) *COMP* mRNA levels (normalised to PPIA) in immortalised abdominal (Abd) and gluteal (Glut) preadipocytes (n = 6) over 14 day adipogenic time-course (data analysed via repeated measures ANOVA). Day 14 TAG accumulation (B) (normalised to cellular protein) and *PPARG2* expression (C) (normalised to *PPIA*) in immortalised preadipocytes cultured in adipogenic medium supplemented with exogenous COMP protein (n = 3). Data presented as mean ± SEM; ANOVA; \*P \< 0.05 compared to untreated cells from same depot.Figure 3

To explore the potential role of *COMP* in adipogenesis, abdominal and gluteal preadipocytes were differentiated in adipogenic medium supplemented with exogenous COMP protein for the 14 day duration. According to analysis via ANOVA with post-hoc T-tests, no effect was observed at 50 ng/ml but treatment with 500 ng/ml COMP protein significantly increased final TAG accumulation by ∼1.25-fold ([Figure 3](#fig3){ref-type="fig"}B) and expression of the adipogenic marker *PPARG2* by ∼1.5-fold ([Figure 3](#fig3){ref-type="fig"}C) in both abdominal and gluteal preadipocytes. On the contrary, culturing abdominal and gluteal preadipocytes in the presence of increasing doses of exogenous COMP protein (50 ng/ml or 500 ng/ml) for 48 h had no effect on the rate of cell proliferation (data not shown).

4. Discussion {#sec4}
=============

COMP is a matricellular protein that plays a key role in bone and cartilage biology [@bib35] as well as processes such as inflammation and angiogenesis [@bib6]. The data presented in this study highlight that: *COMP* is expressed by AT in a depot-specific manner; *COMP* expression in AT and circulating COMP levels are positively correlated with BMI/overall adiposity; and exogenous COMP protein enhanced adipogenesis. These results identify *COMP* as a novel regulator of human AT biology and thereby highlight a previously unknown role for this multi-functional protein.

As most differentially-expressed genes between white AT depots tend to be development-related transcriptional regulators such as *HOX* genes [@bib16], [@bib17], [@bib18], the identification of an ECM component exhibiting depot-specific expression in AT is somewhat novel and may have relevance to regional AT distribution, a strong determinant of metabolic health [@bib34]. Despite being differentially expressed, however, neither subcutaneous abdominal or gluteal *COMP* AT mRNA levels nor circulating COMP protein levels were associated with regional AT accumulation. The data instead suggested that subcutaneous abdominal and gluteal AT *COMP* mRNA and plasma COMP protein levels reflect overall adiposity.

COMP protein was readily detectable in plasma and circulating COMP levels were significantly elevated in overweight/obese individuals compared to normal-weight controls. Furthermore, the observation that circulating COMP protein levels were positively correlated with BMI and total fat mass percentage in men and women is consistent with other reports that plasma COMP levels correlate positively with BMI [@bib36] and decline upon weight loss [@bib37]. Together these observations prompted the suggestion that COMP may represent a novel adipokine akin to THBS1 [@bib10]. However, COMP release from AT *in vivo* could not be detected. This may be due to the slow turnover of COMP protein in AT and/or the nature of the plasma sample donors (i.e. healthy, normal weight women). It remains to be seen whether COMP release from AT would be detectable in overweight/obese men, individuals who would be predicted to have higher levels of AT *COMP* expression given the current data.

AT probably makes a contribution to the circulating pool of COMP (which likely increases in proportion to adiposity) although the majority likely derives from cartilage [@bib37] and bone [@bib19] with the vasculature [@bib38], liver [@bib39], and immune system [@bib40] representing other potential sources. It is currently unclear what function circulating COMP serves. COMP may play an endocrine role that co-ordinates the activity of different tissues (e.g. bone and AT). Further studies are required to explore whether circulating COMP protein is a biomarker whose levels reflect not only adiposity but metabolic health parameters (e.g. fasting glucose and insulin levels) and/or the progression of obesity-related diseases such as osteoarthritis [@bib37]; such a multi-faceted biomarker could inform diagnostic, prognostic and management decisions in a clinical setting.

Alternatively, plasma levels may reflect COMP turnover in the aforementioned tissue types and therefore provide insight into their ECM composition and turnover. Indeed, a recent report identified plasma COMP as a sensitive, non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis [@bib41], consistent with the finding that exogenous COMP protein promotes collagen deposition in hepatic stellate cells [@bib39]. As COMP co-ordinates collagen fibrillogenesis [@bib20] and is involved in the tissue injury response [@bib5], it would be worth exploring whether COMP mediates collagen deposition in AT (and/or other tissues). COMP-mediated collagen deposition might represent an important aspect of the ECM remodelling which supports adipogenesis and adipocyte function in developing and mature AT [@bib42]. However, if this process occurs to an excessive level in obesity, potentially driven by increased *COMP* expression, it may promote AT fibrosis which can negatively affect adipocyte and AT function. If this were the case, it would implicate COMP in subcutaneous AT dysfunction and the development of obesity-associated insulin resistance and metabolic disease [@bib43], [@bib44].

With gene expression and immunohistochemistry analyses confirming that COMP is a highly differentially expressed matricellular protein in human AT, the importance of the ECM to AT biology and overall metabolic health should be acknowledged. The ECM plays a crucial role in determining the capacity of AT to expand [@bib45] as well as the mechanism by which it expands [@bib46]. Experimental data indicate there is regional variation in the mechanism by which human subcutaneous AT expands; abdominal AT reportedly expands via hypertrophy whereas gluteo-femoral AT expands via hyperplasia [@bib47]. As adipocyte size represents an important index of AT function and metabolic health - in which smaller adipocyte size is associated with increased insulin sensitivity [@bib48] - future studies could investigate the relationship between *COMP* expression (mRNA and protein) in subcutaneous abdominal and gluteal AT, adipocyte size, (regional) adiposity, and metabolic health.

Supplementation of adipogenic medium with exogenous COMP protein enhanced *PPARG2* expression and TAG accumulation (but did not affect proliferation) of subcutaneous abdominal and gluteal preadipocytes. AT *COMP* expression was significantly increased under circumstances involving AT expansion (i.e. obesity), suggesting that COMP may act as a paracrine factor which enhances adipogenesis and/or TAG accumulation in adipocytes. Although the mechanism(s) employed by COMP to exert this effect remain unclear, they may involve physical interaction with ECM components such as collagens, fibronectin, growth factors (e.g. members of the transforming growth factor-β superfamily), and/or integrin [@bib35].

Alternatively, COMP may activate signalling pathways which modulate adipogenesis. COMP protein has been reported to activate extracellular signal-regulated kinase (ERK)-1/2 signalling in rat hepatic stellate cells via cluster of differentiation (CD)-36 receptors [@bib39]; ERK1/2 signalling is crucial for adipogenesis [@bib49]. As *CD36* expression increases in preadipocytes during adipogenesis [@bib27], COMP\'s pro-adipogenic effect may involve activation of ERK1/2 signalling via CD36 during the latter phase of differentiation. It should be noted that while COMP is differentially expressed in subcutaneous AT, it exerted pro-adipogenic effects in both abdominal and gluteal preadipocytes. Although the biological significance of COMP\'s depot-specific pattern is currently unclear, this observation supports the notion that adipogenesis occurs in a depot-specific manner [@bib34].

In summary, COMP is a matricellular protein that exhibits a striking depot-specific expression pattern in AT. *COMP* expression in abdominal and gluteal AT as well as circulating COMP levels were positively correlated with BMI/adiposity but not with regional AT distribution. Exogenous COMP protein promoted adipogenesis in subcutaneous abdominal and gluteal preadipocytes although the mechanism(s) employed remain unclear. These data identify COMP as an intriguing novel regulator of AT biology and also highlight the important yet poorly understood role of the ECM in AT.
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[^1]: Note -- BMI correlations are age- and insulin-corrected. \*P \< 0.05.
